Equity Components [Axis] Preferred Stock Common Stock Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Loss Sub Total Noncontrolling Interest Product and Service [Axis] Product [Member] Management Services [Member] Related Party [Axis] Alternative Execution Group [Member] Business Acquisition [Axis] Olaregen Litigation Case [Axis] Damages for Unpaid Invoices Breach of contract and detinue Legal Entity [Axis] KSKZ Management [Member] ALTuCELL [Member] Regentys Property, Plant and Equipment, Type [Axis] Computers and technological assets Machinery and Equipment [Member] Furniture and Fixtures [Member] Leasehold Improvements [Member] Finite-Lived Intangible Assets by Major Class [Axis] Noncompete Agreements [Member] Developed Software/Technology [Member] In Process Research and Development [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreements [Member] Investors Financial Instrument [Axis] Principal Investor Interest Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Subsidiaries [Member] Liability Class [Axis] Derivative Liability Convertible Notes Derivative Liability Warrants Medisource Pantheon [Member] Range [Axis] Minimum [Member] Maximum [Member] Equity Purchase Agreement [Member] Oasis Capital, LLC Share Exchange Agreement NGIO Plan Name [Axis] Stock Option Plan 2006 Stock Option Plan 2017 Award Type [Axis] Stock Options Stock Option Plan 2019 Antidilutive Securities [Axis] Convertible Debt Stock options Warrants Generex Pharmaceuticals HDS [Member] Class of Stock [Axis] Series A Cumulative Redeemable Perpetual Preferred Stock, Accumulated Other Comprehensive Income WWDT Medisource and Pantheon Discover Growth Fund [Member] Iliad [Member] Clinical trial agreement [Member] NSABP [Member] COVID-19 Collaboration Agreement [Member] Transaction Type [Axis] Pre-Commercialization Stage [Member] Commercialization Stage [Member] Intellectual Property [Member] Patents [Member] Long-term Debt, Type [Axis] TwoNotes [Member] lender [Member] Lender [Member] Promissory note [Member] Vendors Security Purchase Agreement [Member] Accredited Investors [Member] Series A Warrants [Member] Series B Warrants [Member] Series C Warrants [Member] Series D Warrants [Member] Non-vested Options [Member] Veneto Subsequent Event Type [Axis] Subsequent Event [Member] Oasis [Member] Warrants [Member] Officers NDS Document And Entity Information Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Incorporation, State or Country Code Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity File Number Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Interactive Data Current Entity Common Stock, Shares Outstanding Statement [Table] Statement [Line Items] ASSETS Current assets Cash and cash equivalents Accounts receivable, net Inventory, net Other current assets Total Current Assets Property and equipment Goodwill Intangible assets Operating lease right-of-use assets - net Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) Current liabilities Accounts payable and accrued expenses Notes payable, current Payable to foundation for services Interest payable to foundation Loans from related parties Operating lease liabilities - current Refundable advances Deferred tax liability Total Current Liabilities Notes payable - noncurrent, net of debt discount Derivative liability Common stock payable Total Liabilities Redeemable non-controlling interest (Note 10) Stockholders' equity (defiency) (Note 9) Common stock, $0.001 par value; 750,000,000 authorized shares; 108,037,614 and 82,251,801 issued and outstanding as of October 31, 2020 and July 31, 2020, respectively Series A Cumulative Redeemable Perpetual Preferred Stock, $0.001 par value per share; 1,000,000 authorized and no shares issued and outstanding as of both October 31, 2020 and July 31, 2020, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Non-controlling interest Total stockholders' deficiency TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Cumulative Preferred Stock, par value Cumulative Preferred Stock, shares authorized Cumulative Preferred Stock, shares issued Cumulative Preferred Stock, shares outstanding Income Statement [Abstract] Revenue Cost of Goods Sold Gross profit Operating expenses Research and development Bad debt expense General and administrative Total operating expenses Operating Loss Other Income (Expense): Interest expense Interest income Change in fair value of common stock payable Change in fair value of derivative liability Other income, net Net loss Net loss attributable to noncontrolling interests Net loss available to common stockholders Net Income per Common Share Basic Diluted Shares Used to Compute Income per Share Basic Diluted Comprehensive loss Net loss available to common stockholders Change in foreign currency translation adjustments Comprehensive loss available to common stockholders Beginning balance, shares Beginning balance, value Stock compensation expense, shares Stock compensation expense, value Shares issued for services, shares Shares issued for services, value Issuance of common stock payable, shares Issuance of common stock payable, value Conversion of debt to equity, shares Conversion of debt to equity, value Issuance of common stock for acquisitions, shares Issuance of common stock for acquisitions, value Reduction of derivative liabilities Issuance of common stock and warrants with attributed derivative liability from PIPE offering, shares Issuance of common stock and warrants with attributed derivative liability from PIPE offering, value Deemed dividend related to issuance of warrants containing derivative liabilities Settlement of derivative liability from exercise of warrants Sale of common stock, shares Sale of common stock, value Exercise of Series D warrants, shares Exercise of Series D warrants, value Cancellation of shares, shares Cancellation of shares, value Purchase of shares in subsidiary Issuance of stock options Currency translation adjustment Net loss Ending balance, shares Ending balance, vlaue Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net (Loss) Income Adjustments to reconcile net (loss) income to net cash used in operating activities: Depreciation and amortization Amortization of operating lease right-of-use assets Stock compensation expense Loss of disposal of fixed assets Amortization of debt discount Change in fair value of derivative liabilities - convertible notes Change in fair value of derivative liabilities - convertible warrants Change in fair value of derivative liabilities - downside protection Bad debt expense Increase in notes payable due to default Change in fair value of common stock payable Changes in operating assets and liabilities, net of effect of acquisitions: Accounts receivable Inventory Accounts payable and accrued expenses Interest payable to foundation Loans from related parties Refundable advance Other current assets Other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Cash received in acquisition of a business, net of cash paid Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES Payment of notes payable Proceeds from note payable Proceeds from issuance of common stock Proceeds from issuance of common stock and warrants in PIPE offering, net of fees of $150,000 Proceeds from exercise of warrants Net cash provided by financing activities Effects of currency translation on cash and cash equivalents Net increase in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental Disclosure of Cash Flow Information Cash paid for interest Cash paid for taxes Supplemental Disclosure of Non-Cash Investing and Financing Activities Reduction of derivative liabilities Discount on derivative liability upon issuance of debt Issuance of common stock for conversion of debt Recording of right of use asset and liability Increase common stock payable Issuance of shares--common stock payable Derivative liability in connection with issuance of warrants from PIPE offering Fees Accounting Policies [Abstract] Organization of Business and Going Concern Summary of Significant Accounting Policies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Inventory Disclosure [Abstract] Inventory Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Debt Disclosure [Abstract] Notes Payable Notes to Financial Statements Derivative Liability Equity [Abstract] Stockholders' Equity Redeemable Non-Controlling Interest Share-based Payment Arrangement [Abstract] Stock-Based Compensation Warrants Warrants Net Income Per Share (EPS) Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Business Combinations Revenue Recognition Adoption of New Accounting Standards Recently Issued Accounting Standards Schedule of revenue recognized Schedule of Inventory Property and Equipment Schedule of Intangible Assets Estimated amortization expense Schedule of notes payable Schedule of Derivative Liabilities at Fair Value Schedule of Issuance of common stock payable Common stock options granted, forfeited or expired and exercised Schedule of non-vested stock options Fair value assumptions used in Black-Scholes option-pricing Schedule of additional warrants Schedule of warrant activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Working capital deficiency Secured promissory note Description Proceeds from related party Revenue recognised Value of damages sought Counterclaim proceeding Lawsuit filing date Name of Plaintiff Settlement of litigation Interest per annum, failure to pay settlement Fixed cost per annum, failure to pay settlement Commitments and Contingencies Litigation awards for damages Litigation awards, exercisable shares Exercise price Memorandum of Understanding description Note amount Face amount Original issue discount Intellectual property acquired Accrued Liquidated damages Accrued claim Consulting fees Damages Common stock description Advanced to related party Stock Purchase Agreement description Legal fees Interest accrued payable to foundation Arbitration fees Arbitration expenses Shares issued for litigation settlement Proceeds from refundable advances Bonus Pre-judgment interest Bonus compensation description Accrued claim Raw materials Finished goods Total Inventory Property and equipment Less accumulated depreciation Property and equipment, net Depreciation expense Loss on disposal of fixed assets Intangible assets gross Less accumulated amortization Intangible assets net Estimated Useful Lives For the nine months ended July 31, 2021 2022 2023 2024 2025 Thereafter Total Amortization expense Balance of notes paybale at beginning Increase in debt due to default Conversions Payments Balance of notes payable at end Notes payable Less: debt discount Total debt, net of discount Notes payable, net - noncurrent Notes payable, net - current Statistical Measurement [Axis] Sale of Stock [Axis] Purchase price of note Investor fee Original issue discount Effective interest Interest rate Due date Payment of Promissory Note Accrued interest Common stock issued for conversion debt, Shares Common stock issued for conversion debt, Value Derivative liability Debt discount Notes payable Closing costs Proceeds from loan Options issued Derivative liabilities at beginning Additions during the period Change in fair value Change due to conversion / exercise Derivative liabilities at end Balance as of July 31, 2020 Issuance of common stock payable Balance as of October 31, 2020 Stock compensation expense Stock Issued During Period, Shares Issued for Services Stock Issued During Period, Value, Issued for Services Issuance of common stock payable, shares Issuance of common stock payable, amount Common stock to be issued Decrease in derivative liability Common stock issued for acquisition Stock Price Cancellation of common stock Number of shares exchanged LOI Terms Common stock purchased Number of common stock issued Purchase price of shares Proceeds from issuance of stock Attorneys fees Shares issued price per share Shares reserved for future issuance Warrants issued Exercise price Non-controlling interest Percentage of non-controlling interest Deemed dividend Decrease in Accumulated Deficit Redeemable Non-Controlling Int Options Outstanding, Beginning Options Granted Options Forfeited or expired Options Exercised Options Outstanding, End Weighted Average Exercise Price per Share, Beginning Weighted Average Exercise Price per Share, Granted Weighted Average Exercise Price per Share, Forfeited or expired Weighted Average Exercise Price per Share, Exercised Weighted Average Exercise Price per Share, End Weighted Average Remaining Life Options Outstanding (Years) Weighted Average Remaining Life Options Granted Weighted Average Remaining Life Options Forfeited or expired Aggregate Intrinsic Value Options, Outstanding Beginning Aggregate Intrinsic Value Options Granted Aggregate Intrinsic Value Options, Outstanding Ending Non-vested Options Outstanding, Beginning Non-vested Options Granted Non-vested Options Expired Non-vested Options Cancelled Non-vested Options Vested Non-vested Options Outstanding, End Weighted Average Grant Date Fair value, Beginning Weighted Average Grant Date Fair value, Granted Weighted Average Grant Date Fair value, Expired Weighted Average Grant Date Fair value, Cancelled Weighted Average Grant Date Fair value, Vested Weighted Average Grant Date Fair value, End Exercise price Time to expiration Risk-free interest rate Estimated volatility Expected dividend Stock price at valuation date Common stock reserved for future issuance Common stock reserved for future awards Market value Options vested Compensation expense Unrecognized compensation costs Unrecognized compensation period Vesting period Options granted Options granted per share Initial Exercise Price Initial Warrants Issued Additional Warrants Issued Reset Exercise Price Total Warrants from PIPE deal Number of Warrants Outstanding at beginning Number of Warrants Issued Number of Warrants Exercised Number of Warrants Expired Number of Warrants Outstanding at end Weighted Average Exercise Price per Share Outstanding at beginning Weighted Average Exercise Price per Share Issued Weighted Average Exercise Price per Share Exercied Weighted Average Exercise Price per Share Expired Weighted Average Exercise Price per Share Outstanding at end Weighted Average Remaining Life of Warrants Outstanding at beginning (Years) Weighted Average Remaining Life of Warrants Issued Weighted Average Remaining Life of Warrants Exercised Weighted Average Remaining Life of Warrants Outstanding at end (Years) Aggregate Intrinsic Value Warrants Outstanding at beginning Aggregate Intrinsic Value Warrants issued Aggregate Intrinsic Value Warrants Exercised Aggregate Intrinsic Value Warrants Outstanding at end Warrants outstanding Number of Warrants issued and exercised Total Pre-tax gain or (loss) arising from domestic operations Pre-tax (losses) arising from foreign operations NOL carryforwards Decrease in deferred tax assets Options exercised Proceeds from options exercised Agreement description Contracted amount Project cost Damages For Unpaid Invoices [Member] Breach Of Contract [Member] Percentage of interest expense directly attributable to an award in settlement of litigation. Stock Option Plan 2006 [Member] Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax Shares, Outstanding BadDebtExpense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable and Accrued Liabilities InterestPayablesToFoundation Increase (Decrease) in Due to Related Parties Increase (Decrease) in Other Current Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) ReductionOfDerivativeLiabilities WarrantsTextBlock Property, Plant and Equipment [Table Text Block] Other Commitments, Description AccruedClaim Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Notes Receivable, Related Parties Derivative Liability, Fair Value, Gross Liability Derivative Liability [Default Label] CommonStockPayable Share-based Payment Arrangement, Expense Stock Issued During Period, Shares, Other NoncontrollingInterest Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised AggregateIntrinsicValueWarrantsOutstanding Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount